APTO:NSD-Aptose Biosciences Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.58

Change

-0.21 (-3.63)%

Market Cap

USD 0.51B

Volume

0.59M

Average Target Price

USD 12.00 (+115.05%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.69 (-0.26%)

USD68.72B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

-7.73 (-1.37%)

USD60.13B 21.90 16.92
SGEN Seattle Genetics, Inc

+0.16 (+0.09%)

USD31.19B N/A N/A
MRNA Moderna, Inc

-1.99 (-2.96%)

USD26.58B N/A N/A
RPRX Royalty Pharma plc

-1.55 (-3.71%)

USD25.36B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

-0.41 (-0.36%)

USD24.64B 30.43 27.52
BGNE BeiGene, Ltd

+1.89 (+0.69%)

USD24.64B N/A N/A
GMAB Genmab A/S

-1.06 (-2.94%)

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

+0.13 (+0.15%)

USD19.69B N/A N/A
INCY Incyte Corporation

-0.90 (-1.05%)

USD18.80B 47.64 35.20

ETFs Containing APTO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.59% 54% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.59% 53% F 57% F
Trailing 12 Months  
Capital Gain 133.47% 87% B+ 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 133.47% 87% B+ 92% A-
Trailing 5 Years  
Capital Gain 11.60% 68% D+ 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.60% 67% D+ 49% F
Average Annual (5 Year Horizon)  
Capital Gain 55.85% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.85% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 115.51% N/A N/A N/A N/A
Risk Adjusted Return 48.35% N/A N/A N/A N/A
Market Capitalization 0.51B 66% D 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.48 33% F 21% F
Price / Cash Flow Ratio -23.54 83% B 89% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -74.05% 46% F 18% F
Return on Invested Capital -49.73% 62% D- 19% F
Return on Assets -43.14% 24% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.57 61% D- 57% F
Short Percent 2.22% 78% C+ 59% F
Beta 0.95 75% C 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector